NCT00306514已完成1 期
A Phase IIa Study to Evaluate Safety, Tolerability, and Immunogenicity of a Melan-A VLP Vaccine in HLA-A2 Positive Patients With Stage III/IV Malignant Melanoma
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 试验地点
- 2
研究概览
简要总结
The purpose of this study is to evaluate whether vaccination with a Melan-A VLP vaccine leads to a specific cellular immune response in patients with malignant melanoma at advanced stage of the disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Able to provide written informed consent
- •Able and willing to complete all protocol requirements
- •Age: 18 years and older
- •Histologically confirmed stage III or IV melanoma
- •HLA-A*0201 haplotype
- •Expected survival of at least 6 months
- •ECOG performance status of 0 or 1
- •At least one and no more than 2 previous systemic therapies for metastatic melanoma
- •Able to undergo computed tomography (CT) scan/ magnetic resonance imaging (MRI) scan for tumor assessment.
- •Lack of response to or progression after most recent systemic therapy for metastatic melanoma.
- •Adequate organ and bone marrow functions
- •All adverse events (AEs) from prior anticancer therapy have resolved to ≤ Grade 1
- •Sexually active males should use adequate contraception throughout the study period and 3 months thereafter.
- •Females of child bearing potential should use adequate contraception throughout the study period and 3 months thereafter, that can be oral contraception or a double-barrier local contraception (intra-uterine device plus condom or spermicidal gel plus condom), and have a negative serum pregnancy test within 4 weeks prior to the first dose of the vaccine.
排除标准
- •Pregnant or nursing
- •Use of an investigational drug within 30 days before enrollment
- •Known or suspected brain metastases
- •Active malignancy in the 5 years prior to enrollment other than melanoma, basal cell carcinoma or cervical carcinoma in situ.
- •Major surgery within 4 weeks prior to enrollment.
- •Current use of an immunosuppressive drug or any concomitant medication that could potentially interfere with the study drug.
- •Presence of significant cardiovascular, renal, pulmonary, endocrine, infectious, or neurological disorders.
- •Serum tests positive for HIV, hepatitis B virus (HBV), hepatitis C virus (HCV).
- •Active autoimmune diseases or severe allergies.
- •Known type 1 allergy.
- •Current diagnosis or history of relevant and severe psychiatric disorder that compromises the patient's ability to understand the patient information, to give informed consent, to comply with the trial protocol or to complete the study.
- •Blood donation or loss of > 400mL within 8 weeks prior to inclusion.
- •Hemoglobin (Hb) < 10g/dL
- •Abuse of alcohol or other recreational drugs.
- •Previous vaccination with a Melan-A peptide analogue.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non-pregnant Women 18-40 Years of Age.Infection by Streptococcus Group BNCT02459262Minervax ApS240
已完成
2 期
Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma PatientsMalignant MelanomaNCT00306553Cytos Biotechnology AG
已完成
1 期
A Safety and Immunogenicity Trial in Adults 65 Years of Age or Over to Prevent InfluenzaInfluenzaNCT00706732AlphaVax, Inc.28
Unknown
1 期
Lentivirus Transduced Acute Myeloid Leukaemia Blasts Expressing B7.1 (CD80) and IL-2Leukemia, Myeloid, AcuteNCT00718250King's College Hospital NHS Trust24
Unknown
2 期
Safety and Immunogenicity of Venezuelan Equine Encephalomyelitis Vaccine in Healthy AdultsVenezuelan Equine Encephalomyelitis Virus DiseaseNCT03051386U.S. Army Medical Research and Development Command500